Veru Reports Q3 FY2026: Net Loss $7.0M, Cash $23.9M; PLATEAU Trial Fully Enrolled
Veru Inc. reported Q3 FY2026 results for the quarter ended June 30, 2026. Net loss was $7.0M, or $0.30 per share, with operating loss from continuing operations of $7.7M. Cash was $23.9M. The company said its Phase 2b PLATEAU trial is fully enrolled (239 patients) and interim analysis is expected in Q1 2027.
How this was made
The 30-second read
Why it matters
Traders can update expectations for the next major catalyst (Q1 2027 interim analysis) while reassessing funding risk given operating losses and cash on hand.
Market read
This is a combined financial and clinical execution update that refines the event timeline and burn-rate backdrop for a small-cap biotech.
What to watch
Cash balance ($23.9M) and rising R&D expense ($4.35M vs $3.02M) could increase dilution or financing risk before Q1 2027, offsetting the clinical timeline improvement.
Background
Veru is advancing enobosarm plus semaglutide in the PLATEAU Phase 2b trial and reported Q3 FY2026 financials for the quarter ended June 30, 2026.
Ticker impact
Veru reported Q3 FY2026 net loss of $7.0M and said its PLATEAU Phase 2b trial is fully enrolled, with interim analysis due in Q1 2027.
Likely supportive for risk appetite into the Q1 2027 interim, but near-term downside risk remains from continued operating losses and limited cash runway.
Full enrollment reduces trial execution risk, but the article also highlights ongoing operating losses and modest cash balance, which can cap upside until interim efficacy/safety data.
Market effects
Adds incremental datapoint for obesity/weight-loss pharmacology pipeline competition, particularly GLP-1 combination strategies and lean-mass preservation claims.
No clear regional market linkage beyond US small-cap biotech sentiment.
Limited; trial enrollment and interim timing are company-specific and not a cross-market macro driver.
Counterpoint
Full enrollment does not guarantee positive interim results; the stock may still re-rate lower if interim efficacy or DXA lean-mass endpoints disappoint.
Key entities
- companyVeru Inc.
Reported Q3 FY2026 net loss and announced PLATEAU Phase 2b full enrollment, with interim analysis expected in Q1 2027.
- partnerNovo Nordisk
Entered a clinical supply agreement with Veru for the PLATEAU trial (announced June 2026).
